Abstract
CDC25 dual specificity phosphatases activate the cyclin-dependent kinase complexes, allowing timely ordered progression through out the different phases of the eukaryotic cell cycle. In humans, there are three genes coding for the CDC25A, B and C proteins with both different and redundant specificities and regulations. The CDC25A member of this family acts during the G1 phase and at the G1/S transition by activating the CDK2/cyclin E and CDK2/cyclin A complexes, a function apparently not shared by the other members. In consequence, CDC25A is submitted to extra-cellular signals-dependent regulations involving in particular mitogenic signal transducers, and leading to modifications of its stability, its localization or its activity. In addition, CDC25A is up-regulated in various cancers, and the molecular mechanisms leading to this up-regulation are far from being understood. In this review, we will synthesize the current knowledge about CDC25A molecular regulations, and try to integrate these data in the cell proliferation and apoptotic functions described for the protein.
Keywords: CDC25A phosphatase, cell cycle, proliferation, apoptosis, G1/S transition, oncogenesis
Anti-Cancer Agents in Medicinal Chemistry
Title: CDC25A: A Rebel Within the CDC25 Phosphatases Family?
Volume: 8 Issue: 8
Author(s): Anne Fernandez-Vidal, Anne Mazars and Stephane Manenti
Affiliation:
Keywords: CDC25A phosphatase, cell cycle, proliferation, apoptosis, G1/S transition, oncogenesis
Abstract: CDC25 dual specificity phosphatases activate the cyclin-dependent kinase complexes, allowing timely ordered progression through out the different phases of the eukaryotic cell cycle. In humans, there are three genes coding for the CDC25A, B and C proteins with both different and redundant specificities and regulations. The CDC25A member of this family acts during the G1 phase and at the G1/S transition by activating the CDK2/cyclin E and CDK2/cyclin A complexes, a function apparently not shared by the other members. In consequence, CDC25A is submitted to extra-cellular signals-dependent regulations involving in particular mitogenic signal transducers, and leading to modifications of its stability, its localization or its activity. In addition, CDC25A is up-regulated in various cancers, and the molecular mechanisms leading to this up-regulation are far from being understood. In this review, we will synthesize the current knowledge about CDC25A molecular regulations, and try to integrate these data in the cell proliferation and apoptotic functions described for the protein.
Export Options
About this article
Cite this article as:
Fernandez-Vidal Anne, Mazars Anne and Manenti Stephane, CDC25A: A Rebel Within the CDC25 Phosphatases Family?, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (8) . https://dx.doi.org/10.2174/187152008786847684
DOI https://dx.doi.org/10.2174/187152008786847684 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drug Metabolism and Transport Under Hypoxia
Current Drug Metabolism A Closer Look at α-Secretase
Current Alzheimer Research Salen Mn Complexes Mitigate Radiation Injury in Normal Tissues
Anti-Cancer Agents in Medicinal Chemistry Cancer Immunotherapy: The Role Regulatory T Cells Play and What Can be Done to Overcome their Inhibitory Effects
Current Molecular Medicine Multiple VEGF Family Members are Simultaneously Expressed in Ovarian Cancer: a Proposed Model for Bevacizumab Resistance
Current Pharmaceutical Design Antiviral Drugs that Target Cellular Proteins May Play Major Roles in Combating HIV Resistance
Current Pharmaceutical Design Microglia Phenotype Diversity
CNS & Neurological Disorders - Drug Targets Microenvironmental Determinants of Adult Neural Stem Cell Proliferation and Lineage Commitment in the Healthy and Injured Central Nervous System
Current Stem Cell Research & Therapy Role of Angiogenesis Inhibitors in Colorectal Cancer: Sensitive and Insensitive Tumors
Current Cancer Drug Targets Nucleic Acids-based Nanotherapeutics Crossing the Blood Brain Barrier
Current Gene Therapy How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization
Mini-Reviews in Medicinal Chemistry Glutathione-Triggered Drug Release from Nanostructures
Current Topics in Medicinal Chemistry 19F: A Versatile Reporter for Non-Invasive Physiology and Pharmacology Using Magnetic Resonance
Current Medicinal Chemistry Editorial [Hot Topic: ADAMs: Targets for Drug Discovery (Executive Editor: Marcia L. Moss)]
Current Pharmaceutical Design Flavonoid Kaempferol Inhibits the Proliferation and Survival of Human Leukemia HL60 Cells
Current Drug Therapy Antibody-Targeted RNase Fusion Proteins (ImmunoRNases) for Cancer Therapy
Current Pharmaceutical Biotechnology Mesenchymal Stem Cells: An Emerging Tool for Cancer Targeting and Therapy
Current Stem Cell Research & Therapy Approaches to Improve Cellular Retention of Radiohalogen Labels Delivered by Internalising Tumour-Targeting Proteins and Peptides
Current Medicinal Chemistry Animal Venoms have Potential to Treat Cancer
Current Topics in Medicinal Chemistry Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry